试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-03-13
Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention
编号:NCT01245725登记状态:入组前撤回企业 / 申办者:Medicure
药物 / 成分:Tirofiban (Aggrastat)、Placebo
登记的停止原因(原文):Study was not initiated, change in clinical development
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-03-13
Dose Finding Study of Albuterol Sulfate in Patients With Intermittent or Persistent Mild Asthma
编号:NCT01252758登记状态:入组前撤回企业 / 申办者:Acerus Pharmaceuticals Corporation
药物 / 成分:albuterol sufate DPI (TBS-7) dose 1、albuterol sufate DPI (TBS-7) dose 2、albuterol sufate DPI (TBS-7) dose 3、Placebo
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-03-13
Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia
编号:NCT02661347登记状态:入组前撤回企业 / 申办者:Northwell Health
药物 / 成分:Risperidone、tDCS
登记的停止原因(原文):Difficulty in recruiting patients who met the eligibility criteria.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-03-12
Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer
编号:NCT01188408登记状态:入组前撤回企业 / 申办者:INSYS Therapeutics Inc
药物 / 成分:Liposome Entrapped Docetaxel (LE-DT)
登记的停止原因(原文):Study shut-down in 12/2010 when NeoPharm merged with Insys.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-03-12
An Efficacy and Safety Study of Theraflu Day Powder as Oral Solution for Cold and Flu
编号:NCT02678234登记状态:入组前撤回企业 / 申办者:GlaxoSmithKline
药物 / 成分:Paracetamol, phenylephrine HCl, and vitamin C
登记的停止原因(原文):The clinical phase of the study (from FSFV to LSLV) was never initiated due to the sponsor's decision.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-03-12
An Efficacy and Safety Study of Theraflu Night Powder as Oral Solution for Cold and Flu
编号:NCT02730364登记状态:入组前撤回企业 / 申办者:GlaxoSmithKline
药物 / 成分:Paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C
登记的停止原因(原文):The clinical phase of the study (from FSFV to LSLV) was never initiated due to the sponsor's decision.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-03-07
Magnitude of Changes in 25 OH Vitamin D3 Levels After Vitamin D3 Supplementation
编号:NCT01170507登记状态:入组前撤回企业 / 申办者:King Faisal Specialist Hospital & Research Center
药物 / 成分:vitamin D3 1000 IU orally daily for 5 months、vitamin D3 3000 IU orally daily for 5 months、vitamin D3 5000 IU orally daily for 5 months、Placebo orally daily for 5 months
登记的停止原因(原文):No funding
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-03-07
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS)
编号:NCT03239600登记状态:入组前撤回企业 / 申办者:GlaxoSmithKline
药物 / 成分:GSK2618960 2 mg/kg、Placebo、Methotrexate
登记的停止原因(原文):The study is stopped for Portfolio prioritization.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-03-07
A Bioequivalence Study of SKF101804 Cefixime Versus Cefixime Reference Formulation in Healthy Adults Under Fasting Conditions
编号:NCT03329547登记状态:入组前撤回企业 / 申办者:GlaxoSmithKline
药物 / 成分:Cefixime test capsule、Cefixime reference capsule
登记的停止原因(原文):Change in commercial strategy
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-03-06
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
编号:NCT00625469登记状态:入组前撤回企业 / 申办者:Rajan Saggar
药物 / 成分:bosentan
登记的停止原因(原文):competing studies did not allow enrollment
查看官方原始记录 ↗